SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates

SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates


Dapaglifozine, marketed under the name Forxiga®, is an anti-diabetic drug in the glifozin class. It is a SGLT-2 transporter inhibitor that reduces glycated hemoglobin, leads to weight loss and improves blood pressure in patients with type 2 diabetes. Dapaglifozine may be given alone or in combination with insulin, an antihyperglycemic agent, depending on the degree of diabetes.
Since the start of the Covid-19 pandemic, physicians have observed that some patients are at increased risk of developing serious complications that could lead to death. One of the factors that may increase this risk are cardiometabolic diseases such as hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, and heart and kidney failure. Since inhibitors of SGLT-2 transporters have shown strong protective effects on the heart and kidneys in patients with type 2 diabetes, dapaglifozine could protect these vital organ systems in Covid-19.

Cat#
Description
Size
Price Excl. VAT
HY-10450-S
 0,5-1mg 
HY-10450-10mg
 10mg 
HY-10450-50mg
 50mg 
HY-10450-1mL
 10mM/1mL 
HY-10450-5mg
 5mg 
HY-128723-1mL
 10mM/1mL 
HY-128723-100mg
 100mg 
HY-128723-10mg
 10mg 
HY-128723-5mg
 5mg 
HY-128723-50mg
 50mg 
HY-10450-100mg
 100mg 
A5854-1ml
 10 mM (in 1mL DMSO) 
A5854-S
 Evaluation Sample 
S2389-2mg
 2mg 
S2389-200mg
 200mg 
408453-100mg
 100mg 
408453-10mg
 10mg 
VD-OTH-0191-25mg
 25 mg 
VD-OTH-0191-5mg
 5 mg 
412820-2,5mg
 2.5mg 
412820-5mg
 5mg 
A5854-5mg
 5 mg 
M1937-10mg
 10 mg 
M1937-50mg
 50 mg 
M1937-5mg
 5 mg 
412449-1mg
 1mg 
412449-2,5mg
 2.5mg 
454521-10mg
 10mg 
Number of results per page : 10 50 250